Developments in pharmacotherapeutic agents for hepatitis B – how close are we to a functional cure?

Khan, Naoshin; Almajed, Mohamed Ramzi; Fitzmaurice, Mary Grace; Jafri, Syed-Mohammed

doi:10.1080/14656566.2023.2211259

Cited by 2 publications

(1 citation statement)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The global health implications of Hepatitis B therapeutic vaccines, exploring the potential benefits, challenges, and their impact on public health as shown in Table 1. The successful development and implementation of hepatitis B therapeutic vaccines could revolutionize the management of chronic HBV infection [59] . By reducing viral load and preventing disease progression, these vaccines have the potential to mitigate the risk of cirrhosis and hepatocellular carcinoma.…”

Section: Global Health Implications Of Hepatitis B Therapeutic Vaccinementioning

confidence: 99%

A critical review of the prospects and challenges of Hepatitis B therapeutic vaccines

Hudu,

Osman,

Abu-Shoura

et al. 2024

Trends Immunother.

View full text Add to dashboard Cite

Hepatitis B therapeutic vaccines hold great promise in the treatment of chronic Hepatitis B virus (HBV) infection. However, like any medical intervention, they also face certain prospects and challenges which forms the aim of this critical review. Therapeutic vaccines offer a targeted approach to manage chronic Hepatitis B infections, aiming to stimulate the immune system to recognise and eliminate infected cells. The potential to halt disease progression holds promise for preventing severe liver diseases associated with chronic Hepatitis B, such as cirrhosis and hepatocellular carcinoma. Therapeutic vaccines, if effective, could contribute to a more equitable distribution of treatment options globally, especially in resource-limited settings. Hepatitis B therapeutic vaccines may play a crucial role in preventing vertical transmission, reducing the global incidence of perinatal HBV infections and improving maternal-child health outcomes. Diverse vaccine platforms and combination strategies, including immunomodulation and checkpoint inhibitors, are advancing, optimising immunogenicity, and eliciting strong immune responses. Tailoring therapeutic vaccines to individual patients based on genetic considerations may enhance efficacy, recognizing the genetic diversity of Hepatitis B. Therapeutic vaccines need to align with global health goals related to infectious disease elimination, contributing to broader efforts to reduce the burden of Hepatitis B worldwide. While Hepatitis B therapeutic vaccines hold significant promise in transforming the management of chronic infections, addressing challenges related to access, viral variability, and long-term monitoring is crucial for their successful integration into global healthcare strategies.

show abstract

Section: Global Health Implications Of Hepatitis B Therapeutic Vaccinementioning

confidence: 99%

A critical review of the prospects and challenges of Hepatitis B therapeutic vaccines

Hudu,

Osman,

Abu-Shoura

et al. 2024

Trends Immunother.

View full text Add to dashboard Cite

show abstract

Current trends and advances in antiviral therapy for chronic hepatitis B

Li,

Liu,

Zang

et al. 2024

Chinese Medical Journal

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection is a global public health concern. Existing antiviral drugs, including nucleos(t)ide analogs and interferon-α, can suppress HBV replication and improve the prognosis. However, the persistence of covalently closed circular DNA (cccDNA), the integration of HBV-DNA into the host genome, and compromised immune responses impede the successful treatment of hepatitis B. While achieving a functional cure of HBV remains elusive with the current treatment methods, this is the goal of new therapeutic approaches. Therefore, developing novel antiviral drugs is necessary for achieving a functional or complete cure for chronic hepatitis B. In recent years, substantial progress has been made in drug discovery and development for HBV infection. Direct-acting antiviral agents such as entry inhibitors, capsid assembly modulators, subviral particle release inhibitors, cccDNA silencers, and RNA interference molecules have entered clinical trials. In addition, several immunomodulatory agents, including toll-like receptor agonists, therapeutic vaccines, checkpoint inhibitors, and monoclonal antibodies, are also making their way toward clinical use. In this review, we summarize the recent progress and limitations of chronic hepatitis B treatment and discuss perspectives on approaches to achieving functional cure. Although it will take some time for these new antiviral drugs to be widely used in clinical practice, combination therapy may become a preferable treatment option in the future.

show abstract

Developments in pharmacotherapeutic agents for hepatitis B – how close are we to a functional cure?

Cited by 2 publications

References 83 publications

A critical review of the prospects and challenges of Hepatitis B therapeutic vaccines

A critical review of the prospects and challenges of Hepatitis B therapeutic vaccines

Current trends and advances in antiviral therapy for chronic hepatitis B

Contact Info

Product

Resources

About